JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ignatowski, T. A.
Right arrow Articles by Bidlack, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ignatowski, T. A.
Right arrow Articles by Bidlack, J. M.

Vol. 284, Issue 1, 298-306, 1998

Detection of Kappa Opioid Receptors on Mouse Thymocyte Phenotypic Subpopulations as Assessed by Flow Cytometry1

Tracey A. Ignatowski and Jean M. Bidlack

Department of Pharmacology and Physiology, University of Rochester, School of Medicine and Dentistry, Rochester, New York

Recent studies have shown kappa opioid receptor labeling on the R1EGO thymoma cell line by indirect immunofluorescence and flow cytometric analysis. The present study used a fluorescein-labeled arylacetamide (FITC-AA), a kappa opioid ligand, in conjunction with biotin-conjugated anti-fluorescein IgG and extravidin-R-phycoerythrin (PE), along with double-labeling with antibodies against specific immune cell surface markers to determine which subpopulation(s) of thymocytes express the kappa opioid receptor. Thymocytes, isolated from 6- to 8-week-old C57BL/6ByJ mice, incubated with FITC-AA followed by the PE amplification procedure, demonstrated labeling of the kappa opioid receptor. This labeling was inhibited 55 ± 4% above background by excess nor-binaltorphimine (nor-BNI), a kappa selective antagonist. This kappa opioid receptor positive population consisted of 58 ± 2% of all gated thymocytes. Phenotypic characterization determined that not only were 64 ± 3% of the gated thymocytes CD4+/ kappa opioid receptor positive, but 60 ± 1% of all thymocytes were CD8+/ kappa opioid receptor positive. Two subpopulations of CD3+ thymocytes, consisting of both mature and immature cells, also displayed labeling for the kappa opioid receptor. Double-labeling of thymocytes with anti-CD4 and anti-CD8 antibodies demonstrated 82 ± 0.5% of these cells were of the double-positive phenotype. Therefore, these findings demonstrate that the thymocytes, which express the kappa opioid receptor, are predominantly of the immature CD4+/CD8+ phenotype. Collectively, these findings not only establish the presence of the kappa opioid receptor on immune cells involved in opioid responsiveness, but further indicate that this technique allows for the identification of distinct lymphocyte subpopulations which express the receptor.


0022-3565/98/2841-0298$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
W. S. Sheng, S. Hu, G. Herr, H. T. Ni, R. B. Rock, G. Gekker, J. R. Lokensgard, and P. K. Peterson
Human Neural Precursor Cells Express Functional {kappa}-Opioid Receptors
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 957 - 963.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
J. M. Bidlack
Detection and Function of Opioid Receptors on Cells from the Immune System
Clin. Vaccine Immunol., September 1, 2000; 7(5): 719 - 723.
[Full Text] [PDF]


Home page
J. Immunol.Home page
L. Zhang and T. J. Rogers
{kappa}-Opioid Regulation of Thymocyte IL-7 Receptor and C-C Chemokine Receptor 2 Expression
J. Immunol., May 15, 2000; 164(10): 5088 - 5093.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. A. Ignatowski and J. M. Bidlack
Differential kappa -Opioid Receptor Expression on Mouse Lymphocytes at Varying Stages of Maturation and on Mouse Macrophages after Selective Elicitation
J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 863 - 870.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.